


## VERIFICATION OF TRANSLATION

I, Satoru TSUTSUI, of 7-1-68 Musashigaoka, Kumamoto-shi, Kumamoto 862-8001, Japan do solemnly and sincerely declare that I have a good understanding of both the Japanese and English languages and that the attached document is, to the best of my knowledge and ability, a true and accurate translation of Japanese Patent Application No. 2003-136876.

Signed this 7th day of June, 2009

A handwritten signature in black ink, appearing to read 'S. Tsutsui', written over a horizontal line.

Satoru TSUTSUI

(Translation)

Japanese Patent Application No.2003-136876 filed on May 15, 2003

[Name of Document] Request for Patent Application

[Code No.] P0228T

[To] Patent Office Commissioner

[IPC] A61P 37/04

[Inventor]

[Address] 2-13-17, Mitoma, Higashi-ku, Fukuoka-shi, Fukuoka, JAPAN

[Name] Seiji SHINKAI

[Inventor]

[Address] 74-10, Nakachaya, Sakai-shi, Osaka, JAPAN

[Name] Masami MIZU

[Inventor]

[Address] 117-7, Nishishinmachi, Himeji-shi, Hyogo, JAPAN

[Name] Kazuo SAKURAI

[Inventor]

[Address] 8-11, Iougaoka, Yawatanishi-ku, Kitakyushu-shi, Fukuoka,  
JAPAN

[Name] Kazuya KOUMOTO

[Inventor]

[Address] 3-13-7, Matsuzaki, Higashi-ku, Fukuoka-shi, Fukuoka, JAPAN

[Name] Munenori NUMATA

[Inventor]

[Address] 3-13-17-101, Hakomatsu, Higashi-ku, Fukuoka-shi, Fukuoka,  
JAPAN

[Name] Takahiro MATSUMOTO

[Patent Applicant]

[ID No.] 396020800

[Name] Japan Science And Technology Agency

[Patent Applicant]

[ID No.] 501100135

[Name] Masami MIZU

[Agent]

[ID No.] 100087675

[Patent Attorney]

[Name] Satoru TSUTSUI

[Fee]

[Ledger No.] 067483

[Amount] 21,000yen

[Appendices]

[Appendix] Specification 1

[Appendix] Drawings 1

[Appendix] Abstract 1

[Name of Document] Specification

[Title of Invention] Immunostimulating Agents

[Claims]

[Claim 1]

An immunostimulating agent which comprises a complex of an immunostimulating oligonucleotide and a polysaccharide having  $\beta$ -1,3-bonds.

[Claim 2]

The immunostimulating agent of claim 1, wherein the immunostimulating oligonucleotide contains an unmethylated CpG motif.

[Claim 3]

The immunostimulating agent of claim 1 or 2, wherein the phosphoric acid backbone of the oligonucleotide is phosphorothioate-modified or phosphorodithioate-modified

[Claim 4]

The immunostimulating agent of claim 1, wherein the polysaccharide having  $\beta$ -1,3-bonds is  $\beta$ -1,3-glucan or  $\beta$ -1,3-xylan.

[Claim 5]

The immunostimulating agent of claim 4, wherein the  $\beta$ -1,3-glucan is selected from among schizophyllan, curdlan, lentinan, pachyman, grifolan, laminaran and scleroglucan.

[Claim 6]

The immunostimulating agent of any one of claims 1 through 5, wherein the polysaccharide is modified with nucleic acid-binding functional group and/or cell membrane-affinitive functional group.

[Claim 7]

The immunostimulating agent of claim 6, wherein the nucleic acid-binding

functional group and/or cell membrane-affinitive functional group are selected from cationic functional groups, a steroid-based functional groups, basic amino acid-based functional groups and peptide-based functional groups.

[Claim 8]

The immunostimulating agent of any one of claims 1 through 7, wherein the complex of the oligonucleotide and the polysaccharide is of a triple helix structure formed through hydrogen bonds and hydrophobic interactions.

[Detailed Description of Invention]

[0001]

[Technical Field to which the Invention Belongs]

The present invention belongs to the technical field of an immunostimulating agent (which may also be called an immunostimulant, immunoactivator or immunoaccelerator) and particularly relates to the provision of a safe and efficacious immunostimulating agent obtained by complexing an immunological oligonucleotide with a novel transfection agent.

[0002]

[Background Art]

An oligonucleotide which is active in stimulating immunoresponse (hereinafter sometimes referred to as an immunostimulating oligonucleotide, immunostimulating nucleic acid or immunostimulating DNA) was discovered by T. Tokunaga and others in 1984 in the course of a search for antitumoral substances against BCG. It was then elucidated that the activity is due to a specific base sequence containing a dinucleotide of cytosine and guanine (5'-CpG-3': the so-called CpG sequence) (Tokunaga, T., et al., J. Natl. Cancer Inst., 72, 955 (1984) : Non-patent Reference 1; Tokunaga, T., et al., J. Natl. Cancer Res., 79, 682 (1988): Non-patent Reference 2).

[0003]

Genome DNAs containing a CpG sequence present in organisms other than vertebrates and plants are also found to have a similar activity. It is considered that a sequence around the CpG core is also important in immunostimulation activity. Particularly, the sequence of 5'-PuPuCpGPyPy-3', in which unmethylated CpG is sandwiched by substituted purines (Pu) and substituted pyrimidines (Py), is recognized as a typical unmethylated CpG motif (Krieg, A., et al., Nature, 374, 576 (1995): Non-patent Reference 3).

[0004]

Examples of useful CpG motifs (hexamers) are given below, wherein A denotes adenine, G guanine, T thymine, and U uracil, respectively:

AACGTT, AGCGTT, GACGTT, GGCGTT, AACGTC, AGCGTC, GACGTC, GGCGTC, AACGCC, AGCGCC, GACGCC, GGCGCC, AACGCT, AGCGCT, GACGCT, GGCGCT

An oligonucleotide of 8 to 100 nucleotides containing an above-mentioned sequence has an immunostimulation activity (Japanese Patent Application Publication No.2001-503254: Patent Reference 1)

[0005]

The following are examples of immunostimulating oligonucleotides containing a CpG motif, which have been reported as being effective in activating NK cells, wherein the underlined parts show a CpG motif and the parts with capital letters denote a thiolated DNA (Iho, S., and Yamato, S., Annual Review Immunity, 2001, 137-146 (2002): Non-patent Reference 4):

accgataaccggtgcccggtgacggcaccacg

accgataagcgctgcccggtgacggcaccacg

accgatgacgtcgccggtgacggcaccacg

accgattcgcgagccggtgacggcaccacg  
 gggggggggggggcgatcggggggggggggg  
 ggggggggggggacgatcgtcggggggggggg  
 ggggggggggggaaacgttggggggggggggg  
 GAGAACGCTCGACCTTCGAT  
 TCCATGACGTTCTGATGCT  
 TCTCCCAGCGTGCGCCAT  
 GGggtcaacgttgaGGGGGg

[0006]

There are known several types of sequences as immunostimulating nucleic acids other than CpG motifs. Examples include a T-rich nucleic acid such as 5' TTT3' which is rich in thymidine, a G-rich nucleic acid such as 5' GGG3' which is rich in guanine, a TG-rich nucleic acid which is rich in thymidine and guanine, and a C-rich nucleic acid which is rich in cytosine. Recently these sequences have received considerable attention as non-CpG immunostimulating nucleic acids (Japanese Patent Application Publication No.1996-500738: Patent Reference 2; Japanese Patent Application Publication No.2002-512599: Patent Reference 3; Japanese Patent Application Publication No.2003-51028: Patent Reference 4; Japanese Patent Application No.2003-510290: Patent Reference 5).

[0007]

A characteristic effect of the above-mentioned immunostimulating nucleic acids on immunocytes is that they activate antigen presenting cells. They act directly upon such cells as monocytes, macrophages or dendritic cells to produce immunoenhancing cytokines such as IL-6, TNF- $\alpha$ , IL-12, IFN $\alpha/\beta$ , IL-18 or nitrogen monoxide.

[0008]

Recently there has been seen an increase in the number of patent applications on

nucleic acids for therapeutic purposes or DNA vaccine compositions against immunological diseases. For example, the University of Iowa Research Foundation has proposed a number of sequences based on CpG motifs for use in therapies on adjuvants against diseases or disorders, including immunodeficiencies caused by infections with viruses, bacteria, fungi or parasites, cancers, or acute reduction in the air current due to exposure to lipopolysaccharides or endotoxins (Japanese Patent Application Publication No.1998-506265: Patent Reference 6; Japanese Patent Application Publication No.2001-503267: Patent Reference 7; Japanese Patent Application No.2001-513776: Patent Reference 8).

[0009]

A patent application is found on the use of a CpG motif in DNA vaccines for fishery products (Japanese Patent Application Publication No.1997-285291: Patent Reference 9).

A patent application has also been filed on the use of a CpG motif for preventive purposes against infection with parvovirus in animals (Japanese Patent Application No.2000-509976: Patent Reference 10).

Aside from that set out in Patent Reference 1, a number of sequences exhibiting an immunostimulant activity are also set out in patent applications such as Patent References 11 and 12 (Japanese Patent Application Publication No.2002-517156: Patent Reference 11; Japanese Patent Application No.2002-526425: Patent Reference 12).

[0010]

As in the case of gene therapy using an antisense DNA, an immunostimulating nucleotide is often modified so that the phosphodiester bonds at its phosphoric acid backbone are converted to phosphorothioate bonds so as to be imparted with resistance against nuclease. Besides, it is often a case that an oligonucleotide is used concurrently



with a transfection agent such as a liposome, cationic lipid, or cholesterol, for the purpose of enhancing the affinity with cells.

[0011]

Some retroviruses and adenoviruses provided, at the beginning, a promising prospect in vitro as a transfection agent for antisense DNAs in gene therapy. However, their uses are now very limited because of their inflammatory and immunogenic nature as well as the risk of mutagenesis and integration with the genome due to such naturally occurring viruses (Mulligan, Science, 260, 926-932 (1993): Patent Reference 5; Miller, Nature, 357, 455-460 (1992): Patent Reference 6; Crystal, Science, 270, 404-410 (1995): Patent Reference 7).

[0012]

As an alternative to such natural types of transfection agents for genes, there is proposed an artificial and nonviral carrier, which is easy to handle as compared with viruses and enables assured and efficient introduction of DNAs into cells (Tomlinson and Rolland, J. Contr. Rel., 39, 357-372 (1996): Patent Reference 8).

[0013]

The nonviral, artificial carrier now under extensive studies is polyethyleneimine (PEI). PEI is a cationic polymer, which assumes a three-dimensional branched structure in a variety of adherent cell or suspended cell lines, that can achieve a transfection efficiency above average in some cases (Boussif et al., Gene Therapy, 3, 1074-1080 (1996): Non-patent Reference 9).

[0014]

There have been many patent applications on various types of cationic polymers or cationic lipids, modified with a substituent containing nitrogen atom as in PEI, filed under titles such as gene carrier, transfection agent, pharmaceutical support and the like.

[0015]

However, the present situation is that almost no investigation has been made on the safety of cationic polymers including PEI. While the presence of amino group(s) is generally indispensable in order to render a substance cationic, the substance with amino group(s) is highly bioactive and has a risk of toxicity in the body. As a matter of fact no cationic polymers studied so far have been put into practical use or listed in dictionaries on pharmaceutical additives or the like (The Pharmaceutical Additives Dictionary, Edited by Pharmaceutical Additives Association of Japan, Published by Yakujinipposha: Non-patent Reference 10 & 11).

[0016]

$\beta$ -1,3-glucan is a polysaccharide which has been put into clinical use in intramuscular injection. It has been long known that this polysaccharide assumes a triple helix structure as it occurs naturally (Theresa M. McIntire and David A. Brant, J. Am. Chem. Soc., 120, 699 (1998): Non-patent Reference 12).

[0017]

The in vivo safety of this polysaccharide has already been confirmed since it has been actually put into practice over twenty years as a intramuscular injection in the immunological enhancement treatment against gynaecological cancer (Shimizu et al., Biotherapy, 4, 1390 (1990): Non-patent Reference 13; Hasegawa, Oncology and Chemotherapy, 8, 225 (1992): Non-patent Reference 14).

[0018]

The prior art includes conjugation of  $\beta$ -1,3-glucan with a biomaterial such as DNA for use as a gene carrier. This prior art relates to the preparation of a conjugate of  $\beta$ -1,3-glucan and a bioactive material in which  $\beta$ -1,3-glucan of triple helix structure as it naturally occurs is bonded to the bioactive material through covalent linkage (PCT/US95/14800: Patent Reference 13).

[0019]

Recently, the present inventors and others have discovered that a polysaccharide having  $\beta$ -1,3-bindings in the backbone forms a new type of complex with various nucleic acids when subjected to a specific artificial treatment (PCT/JP00/07875: Patent Reference 14; PCT/JP02/02228: Patent Reference 15; Sakurai, K., et al., J. Am. Chem. Soc., 122, 4520 (2000): Non-patent Reference 15; Sakurai, K., et al., Chem. Lett., 1242 (2000): Non-patent Reference 16).

[0020]

[Problems to be Solved by the Invention]

The object of the present invention is to provide an immunostimulating agent in which an immunostimulating oligonucleotide is complexed with a new type of carrier which is safe and has a high transfection efficiency.

[0021]

[Means for Solving the Problems]

The present inventors have discovered that, by the utilization of a polysaccharide having  $\beta$ -1,3-bonds as a carrier, there can be obtained an immunostimulating agent which is safe and serves to increase the function of an immunostimulating oligonucleotide for excellent immunological enhancement.

Thus, according to the present invention there is provided an immunostimulating agent which comprises a complex of an immunostimulating oligonucleotide and a polysaccharide having  $\beta$ -1,3-bonds.

[0022]

[Best Mode for Carrying Out the Invention]

In the present invention an immunostimulating oligonucleotide is used as the main agent. The immunostimulating oligonucleotide for use in the present invention is an oligonucleotide which stimulates the immune response to enhance immunity, and is

exemplified by a variety of oligonucleotides as described in the aforementioned references, but is not limited thereto. As the immunostimulating oligonucleotide to which the present invention is directed, is preferably used an oligonucleotide containing an unmethylated CpG motif, a variety of which are described in the aforesaid references. There can be also used a non-CpG type of immunostimulating oligonucleotide (an immunostimulating oligonucleotide other than CpG motif), examples of which are also described in the foregoing. Such non-CpG immunostimulating oligonucleotide can be utilized alone or in combination with CpG motif(s). These oligonucleotides, when administered, act on immunocytes such as macrophage to enhance immunity through the production of cytokines and other functions.

[0023]

For an increased resistance to nuclease, the phosphoric acid backbone of the oligonucleotide for use in the present invention is generally modified so that the phosphodiester bonds at the backbone are converted to phosphorothioate or phosphorodithioate bonds. An oligonucleotide having all or a part of the phosphodiester bonds unconverted may also be utilized.

[0024]

The immunostimulating agent of the present invention comprises a complex of an immunostimulating agent such as mentioned above and a polysaccharide having  $\beta$ -1,3-bonds, in which the polysaccharide serves as a transfection agent. Preferred polysaccharides having  $\beta$ -1,3-bonds for use in the present invention are  $\beta$ -1,3-glucan and  $\beta$ -1,3-xylan. Particularly preferred is  $\beta$ -1,3-glucan selected from among schizophyllan, lentinan, scleroglucan, curdlan, pachyman, grifolan and laminaran.

[0025]

While the polysaccharide for use in the present invention mentioned above may

be used as it is native, it is more preferred for the polysaccharide to be modified with nucleic acid-binding and/or cell membrane-affinitive functional groups. By "nucleic acid-binding" is meant the function to interact a nucleic acid so as to enhance the binding between the polysaccharide and the nucleic acid. By "cell membrane-affinitive" is meant affinitive with cell membrane proteins and cell membrane lipids (phospholipids). In the present invention there is preferably used a polysaccharide which is modified with one or both of nucleic acid-binding functional group and cell membrane-affinitive group. Particularly preferred examples of the nucleic acid-binding and/or the cell membrane-affinitive functional groups include a cationic functional group, a steroid-based functional group, a basic amino acid-based functional group, and peptide-based functional group.

[0026]

A cationic functional group is defined by a functional group having positive electric charge (cf. Working Example 2 set out later, for a concrete example). The polysaccharide, when provided with cationic functional groups, has enhanced binding to a nucleic acid through the electrostatic interaction between the positive charge and the negative charge possessed by the nucleic acid such as DNA and RNA. A steroid-based functional group (a concrete example of which is given in Working Example 4 later,) provides the nucleic acid-binding effect by positive charge due to amino acid groups bonded to the steroid ring via a spacer, as well as the cell membrane-affinitive effect due to the steroid ring. A basic amino acid-based functional group, a concrete example of which is given in Working Example 3 set out later, provides the nucleic acid-binding effect by positive charge due to amino groups of the amino acid, as well as the cell membrane-affinitive effect due to the basic amino acid residue. As exemplified by R8 or RGD described in Working Examples 5-7, a peptide-based functional group is a peptide chain containing an amino acid sequence

which will promote the transfection of a nucleic acid primarily due to the affinity to cell membrane. The polysaccharides can be modified so as to be introduced with the above-mentioned nucleic acid-binding and/or cell membrane-affinitive functional groups in an ordinary manner known in the field of organic chemistry. Generally, the polysaccharide is subjected to periodate oxidation of its 1,6-glucopyranoside branches, followed by reductive amination (cf. FIG.1). The details on the reactions are also given in PCT/JP02/02228 (Patent Reference 15) by the present inventors.

[0027]

The preparation of the complex of the immunostimulating oligonucleotide and the polysaccharide according to the present invention is preferably carried out in the manner as detailed in PCT/JP02/02228 (Patent Reference 15). Thus, the polysaccharide typified by  $\beta$ -1,3-glucan, which originally assumes a triple helix structure as it occurs naturally or it is in water, is dissolved in a polar solvent (e.g. dimethyl sulfoxide) to unbind the structure to a single-stranded form, to which a single-stranded nucleic acid is added, followed by the replacement of the solvent by water (renaturation), thereby producing a complex of single-stranded nucleic acid and double-stranded polysaccharide, i.e., the complex suitable for use in the present invention (cf. Working Example 1 set out later). This complex is of noncovalent nature, in which the single-stranded nucleotide and the double-stranded polysaccharide are conjugated to each other to form a triple helix structure through hydrogen bonds and hydrophobic interactions. As the complex is prepared generally in the form of an aqueous solution, it can be highly purified by a relatively simple method such as ultrafiltration for therapeutic and other uses.

[0028]

[Examples]

The characteristic features of the present invention will be more fully described

with reference to the following working examples in terms of the preparation of concrete examples of the immunostimulating agents, the characterization of the immunostimulating agents prepared, and the evaluation of the agents administered in the in vitro tests. The examples are only for exemplifying purposes and not for restricting the invention.

#### Example 1

##### Preparation of immunostimulating agent comprising a complex of $\beta$ -1,3-glucan (schizophyllan) and an oligonucleotide containing an unmethylated CpG motif (CpG DNA)

Triple helix schizophyllan was prepared in accordance with the conventional method as described in the literature reference: Schizophyllum commune. Fies (ATCC 44200) available from ATCC (American Type Culture Collection) was subjected to a stationary culture in a minimal medium for seven days. After removal of the cellular materials and insoluble residues, the supernatant was subjected to a supersonic treatment to yield schizophyllan with a triple helix structure having a molecular weight of 450000. The thus obtained schizophyllan was dissolved in dimethyl sulfoxide (hereinafter designated as DMSO) to form single-stranded schizophyllan and the concentration was adjusted to be 30mg/ml. To 1 $\mu$ l of the solution was added 3 $\mu$ l of pure water, 1 $\mu$ l of 10mM Tris-buffer (pH 7.8) and 5 $\mu$ l of 3mg/ml CpG DNA solution. The solutions thus obtained were all clear and homogeneous (Gregory G. Martin, et al., Am. Chem. Soc. Polymer Prep. 38(1), 253-254 (1997): Non-patent Reference 17; K. Tabata, et. al., Carbohydr., 89, 121-135 (1981): Non-patent Reference 18).

[0029]

The CpG motif-containing oligonucleotide employed is a solid phase-synthesized product and has phosphorothioate bonds containing one dinucleotide sequence of cytosine-guanine (CpG). The total sequence is TCC ATG ACG TTC CTG ATG CT,

with 3' terminal thereof being linked with forty dA's (SEQ ID No.1) (Y. Aramaki, et. al., Biol. Pharm. Bull., 25(3), 351-355 (2002): Non-patent Reference 19).

[0030]

#### Example 2

#### Synthesis of cationic derivative (amino group-modified schizophyllan) and characterization

A cationic derivative (schizophyllan modified with a cationic functional group) was synthesized in accordance with the reaction scheme shown in Fig.1. It is possible to regulate the rate of introduction of amino group by regulating the equivalent number of sodium periodate for the periodate oxidation. Therefore, the same method of synthesis is applicable regardless of the rate of introduction. The present example relates to the synthesis of cationic functional group-modified schizophyllan in which the schizophyllan is introduced with amino groups at a rate of introduction of 4.6, 17, 20 and 36%. The amino group introduced was 2-aminoethanol or spermine. It is possible to regulate the rate of introduction of the amino group by regulating the equivalent number of the sodium periodate with respect to the branching glucose moiety. The experimental results are shown in Example 3. In the manner as described in Example 1 was obtained schizophyllan having a molecular weight of 450000. 100mg of the thus obtained schizophyllan was dissolved in 100ml water. To the resultant solution was added slowly an aqueous solution of sodium periodate (in an equivalent of 10%, 40%, 50% or 500% (an excess amount) based on the branching glucose of the schizophyllan) and stirring was performed for two days at 4°C. The reaction solution was subjected to dialysis through a membrane (with an exclusion limit of 12000), followed by lyophilization. The white solid product was dissolved in 20ml dimethyl sulfoxide. To the resultant solution was added 2ml of 2-aminoethanol or spermine (a large excess: more than 10000 equivalents) and then stirring was performed for two



days at room temperature. After the excess sodium borohydride was deactivated with acetic acid, the reaction solution was subjected to dialysis (acidic aqueous solution, basic aqueous solution and distilled water) through a membrane (exclusion limit: 12000), followed by lyophilization to yield the cationic derivative.

[0031]

The rate of introduction of the amino group was determined on microanalysis of nitrogen by elemental analysis (low detection limit: 0.05%). The microanalysis of nitrogen was performed three times for each sample, with the results as shown Table 1. The molecular weight was examined through gel permeation chromatography (GPC) and also by measuring the viscosity, showing that it is identical to the molecular weight of the starting material.

[0032]

[Table 1]

Periodate Equivalent(%)	10	40	80	500
Amino Group Introduction Rate	4.6 – 4.7	16.3 – 17.8	19.3 – 20.8	35.2 – 37.4

[0033]

### Example 3

#### Synthesis of amino acid derivative (arginine-modified schizophyllan) and characterization

In accordance with the reaction scheme as shown in FIG.1, an amino acid-derivative was synthesized. The rate of introduction of the amino acid was regulated in the same manner as in Example 2. The present example relates to the synthesis of arginine-modified schizophyllan with rates of introduction of arginine of 4.6, 17, 20 and 36%.

[0034]

In the manner as described in Example 1, there was obtained schizophyllan having a molecular weight of 450000. The thus obtained schizophyllan, 100mg, was dissolved in 100ml water. To the resultant solution was added slowly an aqueous solution of sodium periodate (in an equivalent of 10, 40 and 70% on the branching glucose of the schizophyllan) and stirring was performed for two days at 4°C. The reaction solution was subjected to dialysis through a membrane (exclusion limit: 12000), followed by lyophilization. The white solid product was dissolved in 20ml DMSO. To the resultant solution was added 2ml of arginine methyl ester (more than 10000 equivalents) followed by stirring for two hours at room temperature. After the excess sodium borohydride was deactivated with acetic acid, the reaction solution was subjected to dialysis (acidic aqueous solution, basic aqueous solution, and distilled water) through a membrane (exclusion limit: 12000), followed by lyophilization to yield the arginine-modified schizophyllan.

[0035]

The rate of introduction of arginine was determined on microanalysis of nitrogen by elemental analysis (lower detection limit: 0.05%). The microanalysis of nitrogen was performed three times for each sample. The results are shown in Table 2.

[0036]

[Table 2]

Periodate Equivalent	Arginine Introduction Rate
10%	3.6%
40%	9.3%
70%	13.5%

[0037]

#### Example 4

Synthesis of cholesterol derivative (Cholesterol-modified schizophyllan) and

### characterization

In accordance with the scheme as shown in FIG.1, a cholesterol derivative (schizophyllan modified with a steroid-based functional group) was synthesized. The rate of introduction of cholesterol was regulated in the same manner as in Example 2. The present example relates to the synthesis of cholesterol-modified schizophyllan in which the schizophyllan is introduced with cholesterol at the rate of introduction of 4.5%. Thus, 100mg of schizophyllan, as prepared in the manner described in Example 1, was dissolved in 100ml water. To the resultant solution was added sodium periodate 1.65mg (5mol% based on the branching glucose) and stirring was performed for two days at 4°C in the dark. The reaction solution was subjected to dialysis through a membrane (exclusion limit: 12000), followed by lyophilization.

[0038]

The white solid product was suspended in DMSO, followed by addition of a steroid-derivative terminated with an amino group (3 $\beta$ -cholest-5-en-3-yl-N-(2-aminethyl) carbamate as synthesized in the manner described in the literature reference by Ishi et al.) and stirring was performed for two days at room temperature. To the reaction solution was added 100mg of sodium borohydride, two times at an interval of four hours, followed by stirring one day at room temperature. After the excess sodium borohydride was deactivated with acetic acid, the reaction solution was subjected to dialysis through a membrane (exclusion limit: 12000), followed by lyophilization (Tsutomu Ishii, Ritsuko Iguchi, Erwin Snip, Masato Ikeda and Seiji Shinkai, *Langmuir*, 17, 5825-5833 (2001): Non-patent Reference 20).

[0039]

The rate of introduction of cholesterol was determined on microanalysis of nitrogen by elemental analysis (lower detection limit: 0.05%). The microanalysis of

nitrogen was performed three times for each sample. The results are given in Table 3.

[0040]

[Table 3]

Periodate Oxidation Rate	Nitrogen Content	Cholesterol Introduction Rate
5.0%	0.358-0.383%	4.5%

[0041]

#### Example 5

##### Synthesis of peptides containing binding-functional group

In modifying schizophyllan with a peptide chain (peptide-based functional group), it is necessary for the peptide chain to have a functional group capable of binding to schizophyllan. While there are no special restrictions on the binding functional group and the spacer therefor, the present example relates to the synthesis of a peptide chain containing cysteine which includes a thiol moiety: The thiol covalently binds to a maleimide group by Michael addition.

[0042]

Peptide sequences synthesized are an arginine oligomer which is known to have a high affinity to cell membrane (an octamer, referred to as R8: SEQ ID No.2), and a sequence of arginine-glycine-aspartic acid which is known as being recognized by cell adhesion factors (referred to as RGD: SEQ ID No.3), the two sequences being N-terminated with cysteine (cf. FIG.2).

The peptide chains were synthesized by Fmoc method and the products were purified by HPLC (high performance liquid chromatography) (HITACHI L-700, ODS column available from YMC Co., eluting solvent: acetonitrile/distilled water = 5/95 (both containing 0.1vol% trifluoroacetate), forty minutes with a gradient of 20/80). Identification of the products was carried out by MALDI-TOF MS (matrix-assisted laser desorption ionization-time of flight mass spectrometer) (matrix:CHCA) with the

results as shown in Table 4. ("Solid-phase Synthesis Handbook", published by Merck Co." for Fmoc method: Non-patent Reference 21).

[0043]

[Table 4]

Peptide	Calculated	Found
R8	1371.65	1371.20
RGD	450.48	450.40

[0044]

#### Example 6

##### Synthesis of peptide-modified schizophyllan

In accordance with the scheme shown by FIG.3, the respective peptide-chains synthesized in Example 5 were introduced into schizophyllan. The reaction comprised the four steps of periodate oxidation, reductive amination, spacer introduction, and peptide introduction. The rate of introduction of peptide could be regulated by the periodate oxidation. The second and third steps were evaluated for the progress of reaction by elemental analysis. The results are shown in Example 7.

[0045]

Schizophyllan 300mg prepared in Example 1 was dissolved in 300ml of water. To the resultant solution was added an aqueous solution of sodium periodate (9.87mg: in an equivalent of 0.1 (10%) based on the branching glucose of the schizophyllan) and stirring was performed for two days at 4°C under a lightproof condition. The reaction solution was subjected to dialysis through a membrane (exclusion limit: 12000), followed by lyophilization to yield a white solid 1.

[0046]

The white solid product 1 (100mg) was dissolved in 10ml DMSO, a polar organic solvent, and 10ml of 28% ammonia aqueous solution. To the resultant solution was

added 200mg (a large excess) of sodium cyanoborohydride, followed by stirring for four days at room temperature. The reaction solution was subjected to dialysis through a membrane (exclusion limit: 12000), followed by lyophilization to yield a white solid product 2.

[0047]

The white solid product 2 was dissolved in 10ml of DMSO. To the resultant solution was added 100mg (a large excess) of 3-maleimide propionate-N-hydroxysuccinimide ester, followed by stirring for 24 hours at room temperature under a stream of nitrogen. The reaction solution was subjected to dialysis through a membrane (exclusion limit: 12000), followed by lyophilization to yield a white solid product 3.

[0048]

The white solid product 3 was dissolved in 5ml of DMSO. Each of the peptide chains containing cysteine as prepared in Example 5 was dissolved in distilled water. The thus obtained solution was mixed with the DMSO solution. The resultant solution was stirred for two days at room temperature. The reaction solution was subjected to dialysis through a membrane (exclusion limit: 12000), followed by lyophilization to yield each peptide-modified schizophyllan.

[0049]

#### Example 7

##### Characterization of peptide-modified schizophyllan

Characterization was performed for each peptide-modified schizophyllan prepared in Example 6, with respect to the rate of introduction at each step of the reaction by elemental analysis of nitrogen atom, as well as the molecular weight. Table 5 shows the rate of introduction of the functional groups (the rate of modification with the peptides) at the respective steps of the reaction, as measured by the elemental

analysis of nitrogen. The molecular weights were evaluated by means of gel permeation chromatography, which showed that there was no substantial change in the molecular weight due to the peptide modification.

[0050]

[Table 5]

	R8-modified Schizophyllan		RGD-modified Schizophyllan	
Oxidation Rate of the Branch	5%	10%	5%	10%
White Solid Product <u>2</u>	3.7±0.1%	9.4±0.1%	3.7±0.1%	9.4±0.1%
White Solid Product <u>3</u>	3.7±0.3%	2.3±0.3%	3.7±0.3%	2.3±0.3%
Peptide-modified Schizophyllan	0.3±0.1%	0.5±0.1%	1.0±0.1%	1.3±0.3%

[0051]

#### Example 8

Preparation of immunostimulating agent comprising CpG DNA complexed with cationized schizophyllan, amino acid-modified schizophyllan, Cholesterol-modified schizophyllan, or peptide-modified schizophyllan

In aliquots of DMSO were dissolved each of 17, 20 and 36% amino group-modified schizophyllan (hereinafter designated as N-SPG), 4.6% spermine-modified schizophyllan (hereinafter designated as SP-SPG), 3.6, 9.3 and 13.5% arginine-modified schizophyllan (hereinafter designated as Arg-SPG), 4.5% cholesterol-modified schizophyllan (hereinafter designated as Chol-SPG), 0.3 and 0.5% R8-modified schizophyllan (hereinafter designated as R8-SPG) and 1.0 and 1.3% RGD-modified schizophyllan (hereinafter designated as RGD-SPG) to form respective single-stranded modified schizophyllans and the concentration was adjusted to 30mg/ml. Per 1μl of each solution was added 3μl of pure water, 1μl of 10mM Tris-buffer (pH 7.8) and 5μl of the CpG DNA solution (3mg/ml). The solutions thus obtained were all clear and homogeneous.

[0052]

Hereinafter the schizophyllan derivatives as synthesized in Example 2, 3, 4 and 6 are collectively called as chemically modified schizophyllan. Each chemically modified schizophyllan is expressed by such a notation as "R8(0.3)-SPG" in which the numerical value within parentheses indicates the percentage of introduction of each functional group.

[0053]

#### Example 9

#### Electrophoretical confirmation of formation of complex comprising CpG DNA and schizophyllan

As CpG DNA is negatively charged owing to the phosphoric acid groups, it migrates electrophoretically to the anode. Such migration occurs by passing through the network structure of the matrix gel, and therefore the formation of a complex of CpG DNA and schizophyllan reduces the mobility owing to increased molecular weight. Thus, with respect to the complexes of CpG DNA with schizophyllan or chemically modified schizophyllan prepared in the manners as described in Examples 1 and 8, the mobilities were evaluated by electrophoresis, in which the complexes were rendered to migrate on 2% agarose gel in MOPS buffer (20mM MOPS (pH 7.0), 5mM sodium acetate, 1mM EDTA, 3% dimethyl sulfoxide) for one hour at a voltage of 2v/cm. The gel was stained with Gel Star Nucleic Acids Stain (BMA) and visualized on a transilluminator.

[0054]

FIG.4 shows an example of the results of the electrophoresis, from which it is seen that, when schizophyllan or chemically modified-schizophyllan was present, the mobilities decreased, thereby confirming the formation of the complexes.

[0055]



#### Example 10

#### Enhanced production of IL-12 cytokine from mouse-derived intraperitoneal macrophage, stimulated with a complex of CpG DNA and schizophyllan or chemically modified schizophyllan

The Isolation of the mouse-derived intraperitoneal macrophage was carried out in the ordinary manner as described in the literature reference. Thus, a female Balb/c mouse 8 weeks of age was sacrificed by bleeding from the carotid artery. Following sterilization with 70% ethanol, the abdominal skin was cleaved to expose the peritoneum. Cold PBS (phosphate buffered saline) 5ml was injected into the peritoneum, followed by sufficient massage to harvest the fluid. Centrifugation was performed at 1,000 rpm for ten minutes at 4°C using a polypropylene tube. After removal of the supernatant, the resultant was suspended in RPMI1640 medium containing 10% fetal bovine serum ("New Biochemical Experiments 12: Molecular Immunology I, Immunocytes-Cytokines" edited by Biochemical Society of Japan, published by Tokyo Kagakudojin (1989): Non-patent Reference 22).

[0056]

The thus obtained macrophage cells  $2 \times 10^5$ , having been suspended in 100 $\mu$ l of the PPMI1640 medium containing 10% fetal bovine serum, were seeded into a 96-well plate and cultured under 5% CO<sub>2</sub> at 37°C for two hours, so as to render the cells adhered to the plate. To the resultant were added CpG DNA and the complex of CpG DNA and schizophyllan or chemically modified schizophyllan as prepared in Examples 1 and 8, which had been subjected to ultrafiltration (exclusion limit: 3000) to remove the DMSO and readjusted with respect to the concentration. Culturing was conducted at 37°C under 5% CO<sub>2</sub> for 24 hours, followed by the recovery of the culture supernatant.

[0057]

The whole quantity of mouse-derived IL-12 contained in each culture supernatant was measured by utilizing Mouse Interleukin-12 Total ELISA (available from ENDOGEN), in which the measurement was carried out in accordance with the protocol attached. The results are shown in FIG.5. As shown in FIG.5, the total quantity of IL-12 contained in the culture supernatant was higher in the case where there was administered a complex of CpG DNA and schizophyllan or chemically modified schizophyllan, an immunostimulating agent of the present invention, as compared with the case of the administration of CpG DNA alone. It was thus evidenced from the results that the administration of the immunostimulating agent of the present invention enhances the production of cytokine (IL-12) from the macrophage.

[0058]

#### Comparative Example 1

Production of IL-12 cytokine from mouse-derived intraperitoneal macrophage, with a complex of non-CpG DNA (oligonucleotide not containing CpG motif) and schizophyllan or chemically modified schizophyllan

The production of IL-12 cytokine from mouse-derived intraperitoneal macrophage was evaluated in the same manner as in Example 10, by using a sequence of ATG AGC TTC CTG ATG CT, which has phosphorothioate bonds and does not contain any sequence of cytosine-guanine dinucleotide (CpG) (i.e., is not immunostimulating), with the 3' terminus thereof being linked with forty dA's (hereinafter designated as non-CpG DNA: SEQ ID No.2), in place of CpG DNA as used in Example 10. The results are shown in FIG.6 (Y. Aramaki, et. al., Biol. Pharm. Bull., 25(3), 351-355 (2002): Non-patent Reference 23).

[0059]

As shown in FIG.6, there are observed no enhancing effects on the whole quantity of mouse IL-12 contained in the culture supernatant, even when administered with a

complex of non-CpG DNA and schizophyllan or chemically modified schizophyllan, as well as with non-CpG DNA alone. The quantities are substantially the same level as that in the case of use of the culture medium alone without administration of such agents. It is thus evidenced from the results that the complexes composed of an oligonucleotide which is not immunostimulating (non-CpG DNA in the subject Example) will not be effective in immunostimulation (will not produce IL-12, a cytokine).

[0060]

#### Example 11

##### Enhanced production of IL-12 cytokine from mouse-derived macrophage-like cell line J774.A1, stimulated with a complex of CpG DNA and schizophyllan or chemically modified schizophyllan

In the same manner as described in Example 10, the production of IL-12 cytokine was evaluated by using mouse-derived macrophage-like cell line J774.A1 (available from ATCC), which has been reported to enhance the production of IL-12 when treated with an immunostimulating substance, in place of mouse-derived intraperitoneal macrophage as used in Example 10. The results are shown in FIG.7 (E. R. Kandimalla, et al., Bioconjugate Chem., 13(5), 966-974 (2002): Non-patent Reference 24).

[0061]

As shown in FIG.7, the whole quantity of IL-12 contained in the culture supernatant is higher in the case where there is administered a complex of CpG DNA and schizophyllan or chemically modified schizophyllan, an immunostimulating agent of the present invention, as compared with the case of the administration of CpG DNA alone. It is thus evidenced from the results that the administration of the immunostimulating agent of the present invention enhances the production of cytokine (IL-12) from the macrophage, as well as from the mouse-derived intraperitoneal

macrophage as shown in Example 10.

[0062]

[Advantageous Effects of the Invention]

The present invention provides a new type of immunostimulating agent comprising, as carrier, a polysaccharide such as  $\beta$ -1,3-glucan, the safety of which has been established. The immunostimulating agent of the present invention is safe and exhibits an excellent efficacy in immunological enhancement, and therefore has prospective applications in such area as immunotherapy and gene therapy.

[0063]

[Sequence Listing]

#### SEQUENCE LISTING

<110> Japan Science and Technology Agency

<110> MIZU Masami

<120> Immunostimulant

<160> 4

<210> 1

<211> 60

<212> DNA

<213> Artificial S-oligo nucleotide

<220>

<223> Solid phase synthesized nucleotide

<400> 1

tccatgacgt tectgatget aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

<210> 2

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Solid phase synthesized peptide

<400> 2

Arg Gly Asp

1

<210> 3

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Solid phase synthesized peptide

<400> 3

Arg Arg Arg Arg Arg Arg Arg Arg

1

5

<210> 4

<211> 49

<212> DNA

<213> Artificial S-oligo nucleotide

<220>

<223> solid phase synthesized nucleotide

<400> 4

cccccccca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

[Brief Description of the Drawings]

[FIG.1] shows a reaction scheme for synthesizing a modified  $\beta$ -1,3-glucan(schizophyllan) for use in the present invention, as an example, in which schizophyllan is to be modified with an amino group, amino acid-based functional group or cholesterol-based functional group.

[FIG.2] shows the amino acid sequences of R8 peptide and RGD peptide for use in the present invention.

[FIG.3] shows an example of the reaction scheme for synthesizing peptide-modified schizophyllan (R8-SPG and RGD-SPG) for use in the present invention.

[FIG.4] is an agarose gel electropherogram showing that CpG DNA forms a complex with schizophyllan, amino group-modified schizophyllan, arginine-modified schizophyllan, R8-modified schizophyllan, or RGD-modified schizophyllan to compose an immunostimulating agent according to the present invention.

[FIG.5] demonstrates the enhanced production of IL-12 cytokine from mouse-derived intraperitoneal macrophage when stimulated with a complex of CpG DNA and schizophyllan or chemically modified schizophyllan, an immunostimulating agent according to the present invention.

[FIG.6] shows the production of IL-12 cytokine from mouse-derived intraperitoneal macrophage when stimulated with a complex of non-CpG DNA (an oligonucleotide not containing any CpG motif) and schizophyllan or chemically modified schizophyllan.

[FIG.7] demonstrates the enhanced production of IL-12 cytokine from a mouse-derived macrophage-like cell line J774.A1 when stimulated with a complex of CgG DNA and schizophyllan or chemically modified schizophyllan, an immunostimulating agent according to the present invention.

[Name of Document] Abstract

[Abstract]

[Problems] Provided is a new type of immunostimulating agent comprising an immunostimulating oligonucleotide complexed with a carrier which is safe and has a high transfection effect.

[Means for Solution] The carrier complexed with the immunostimulating oligonucleotide to form the immunostimulating agent is a polysaccharide having  $\beta$ -1,3-bonds (preferably  $\beta$ -1,3-glucan such as schizophyllan). A preferred example of the immunostimulating oligonucleotide is one containing an unmethylated CpG motif. The polysaccharide for use is preferably modified with nucleic acid-binding functional group and/or cell membrane-affinitive functional group.

[Selected Figure] None





[Figure 2]


R8

$\text{NH}_2\text{-Cys-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-COOH}$


RGD

$\text{NH}_2\text{-Cys-Arg-Gly-Asp-COOH}$


[Figure 3]




[Figure 4]



[Figure 5]



[Figure 6]



[Figure 7]

